{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"data_sharing_plan":["IPD Sharing (as of July 2023): Yes\nDescription: Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.\nAccess can be requested for all interventional clinical studies:\n* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).\n* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.\nIn addition, access can be requested for all interventional clinical studies in patients:\n* sponsored by Servier\n* with a first patient enrolled as of 1 January 2004 onwards\n* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.\nTime frame: After Marketing Authorisation in EEA or US if the study is used for the approval.\nAccess Criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.\nURL: https://clinicaltrials.servier.com/\nAdditional information available: Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report"],"condition":["Solid Tumor","Advanced solid tumors","Colorectal Neoplasms","Neoplasms"],"disease":["Solid Tumor","Advanced Solid Tumors","Colorectal Neoplasms","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2398753"],"location":["Canada","United States"],"study_start_month":["10"],"keyword":["Anti-EGFR","Triplet combination","Anti-HER2","Adults","Futuximab/modotuximab","Sym21"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers","description":"The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.","dates":{"creation":"2021-10-15"},"accession":"2398753","cross_references":{"ClinicalTrials___gov":["NCT05162755"]}}